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I. Abstract 
 In 2015, over 3.8 million people reported misusing prescription pain medication within 
the last month and over 5.1 million people in the United States admitted to using heroin at some 
point in their lives. Despite the widespread prevalence of opioid abuse, evidence-based 
treatments, such as medication-assisted treatment (MAT), have yet to be made widely available 
and easily accessible to patients. This program plan was designed to recommend strategies to 
effectively incorporate MAT into the primary care setting. Interviews were compiled from key 
informants at primary care clinics with successful MAT programs in the Chapel Hill, North 
Carolina and surrounding area in order to develop a model of practice transformation that could 
be applied to a primary care clinic that does not currently provide MAT services. Ultimately, the 
key factors to consider when implementing MAT in the primary care setting include: provider 
buy-in, the availability of behavioral support staff, and support of key administrative and support 
staff.  
 
II. Background 
 The United States is in the midst of an opioid use epidemic, affecting people of all ages, 
races and socioeconomic backgrounds. Over 100 Americans die each day due to opioid overdose 
1. Fortunately, an evidence-based approach to treating opioid use disorder exists in the form of 
medication-assisted treatment (MAT). MAT describes the use of medications in combination 
with counseling and other therapeutic modalities to provide a more holistic approach to 
substance abuse treatment 2.  MAT is the therapeutic modality of choice for opioid use disorder 
(OUD)3. The primary medications used for the treatment of OUD include methadone, 
buprenorphine (as monotherapy or in combination with naloxone), and naltrexone. 
Unfortunately, some providers remain reluctant to prescribe this treatment for various reasons 
which include but are not limited to:  
1). Apprehension regarding working with a patient population perceived to be difficult;  
2). Fear of negative patient outcomes;  
3). Fear of patient capacity being oversaturated by those wanting MAT;  
4). Not wanting to engage in the extra effort to receive a waiver to prescribe.  
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In order to comprehend how these medications work and to understand why many providers are 
apprehensive to prescribe one opioid to treat the addiction to another, it is necessary to have a 
basic understanding of the history of opioids in the US and the pathophysiology of OUD.  
 
History of Opioid Use 
Opium-based elixirs have been employed for both their euphoric and pain-relieving 
effects since before the Byzantine times 4.  Morphine was first developed in 1804 by Friedrich 
Serturner of Paderborn, Germany as he isolated and neutralized the active ingredient of opium 
with ammonia. Morphine was initially referred to as “God’s own medicine” for its seemingly 
safe and long-lasting effects 4. However, it was soon observed that users become dependent on 
the drug. Morphine was then distilled by Heinrich Dreser with the goal of producing a drug 
without the addictive side-effects of morphine: diacetylmorphine 5. This was later commercially 
introduced by the Bayer Company of Elberfeld Germany as “Heroin”5. 
Heroin was used briefly as a step-down cure for morphine addicts until it was noted that 
heroin withdrawal symptoms paralleled those of morphine 5. Unfortunately, by 1903, the US was 
facing a massive heroin addiction crisis 5. In 1914, the Harrison Narcotics Tax Act was passed, 
which required doctors, pharmacists and other prescribers of narcotics to register and pay a tax in 
order to attempt to curb the prescription of opioids 5. This piece of legislation was one of the first 
of its kind to bring awareness to clinicians about the “highly addictive nature of opioids” and 
regulate their use4. However, the Harrison Act was more pernicious in that it made prescribing 
an opioid to a patient in order to treat opioid addiction illegal. This aspect of the Act would later 
be amended to allow for perscribing of methadone, and later buprenorphine, for opioid use 
disorder. A decade later in 1924, the Heroin Act was passed, which made the importation, 
manufacture and possession of even medicinal heroin illegal 4.  
The late 1990s marked an era of increased lobbying by the pharmaceutical industry to 
increase the use of opioids for all pain types, not limited to cancer and terminal illness 5. This 
lobbying lead to the Joint Commission on Accreditation of Healthcare Organizations 
incorporating pain as the “fifth vital sign” and the training of healthcare providers in 
pharmacological pain management 1,7. Concomitantly, pharmaceutical companies began 
aggressive manufacturing, marketing, and promotion of opioid painkillers 6. Opioid painkillers, 
such as oxycodone, were marketed as reliably safe and efficacious with minimal monitoring 
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needs in the acute pain setting 7. This led to a sharp rise in the number of opioid prescriptions 
written by healthcare providers 7. Additionally, more potent and dangerous synthetic opioids, 
such as fentanyl, were developed and introduced into the market by both medical and non-
medical pathways7.  The result of these changes has been the opioid epidemic in which the US is 
currently entrenched 7.  
 
Physiology of opioid use 
Opioids are defined as “natural and synthetic substances that act at one of the three main 
opioid receptor systems: mu, kappa, and delta”8. Most opioids primarily act on the mu-receptor. 
Kappa and delta opioid agonists have been shown to activate pain inhibitory pathways with 
fewer unwanted side effects that mu-opioid agonists 9. The development of pharmacologic 
agents targeting kappa and delta receptors is still being heavily researched 9. The kappa and delta 
receptors are thought to require specific states of inflammation, that may not always be present, 
to yield efficacious results 9.   
Activation of mu-receptors leads to a cascade of reward, analgesia and withdrawal 8. 
These receptors are located both centrally and peripherally 8. Activation of central mu-receptors 
have the potential to cause respiratory depression, analgesia, euphoria, and miosis 8. Secondary 
messengers, including cyclic adenosine monophosphate (cAMP), are acutely decreased by opioid 
receptor activation and are chronically upregulated with long-term opioid use, resulting in a need 
for increased dosing to achieve the same analgesic effect 8.  
A plethora of compounds and subcategories fall under the umbrella term of “opioids,” 
including heroin, opium, and prescribed opioids. Prescribed opioids consist of subclasses 
including opiates (e.g. morphine and codeine- opioids containing alkaloid compounds), semi-
synthetic synthetic opioids (e.g. oxycodone and hydrocodone), and synthetic opioids (e.g. 
fentanyl and methadone) 8. In addition to these subclasses, opioids are further classified as 
agonists, partial-agonists or antagonists depending on their receptor binding and affinity 8. The 
most commonly abused opioids (e.g. hydrocodone, oxycodone, codeine) are full agonists 3. 
Broadly, the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) 
incorporates opioid abuse and opioid dependence into one comprehensive disorder: opioid use 
disorder (OUD) 3. OUD is a type of substance use disorder, defined as the state when “recurrent 
use of alcohol and/or drugs causes clinically and functionally significant impairment”, and “can 
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involve misuse of prescribed opioid medications, use of diverted opioid medications, or use of 
illicitly obtained heroin”3. The DSM-V criteria emphasizes that the hallmarks opioid use disorder 
is use that leads to clinical impairment and personal harm in essential domains of daily life. We 
present the criteria in Text Box I.  
Text Box 1  
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Medication-assisted treatment (MAT) of opioid use disorder 
Three compounds are utilized in medication-assisted treatment of OUD: methadone, 
buprenorphine, and naltrexone. Methadone is a full opioid agonist and has been used since the 
 “A problematic pattern of opioid use leading to clinically significant impairment or distress, as manifested 
by at least two of the following, occurring in a 12-month period” 3:  
1. Opioids taken in larger amounts or over a longer period than was intended; 
2. A persistent desire or unsuccessful efforts to cut down or control opioid use; 
3. A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or recover 
from its effects; 
4. Craving, or a strong desire or urge to use opioids; 
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school, or home; 
6. Continued opioid use despite having persistent or recurrent social or interpersonal problems caused 
or exacerbated by the effects of opioids; 
7. Important social, occupational, or recreational activities are given up or reduced because of opioid 
use; 
8. Recurrent opioid use in situations in which it is physically hazardous; 
9. Continued opioid use despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by the substance; 
10. Tolerance, as defined by either of the following:  
a. A need for markedly increased amounts of opioids to achieve intoxication or desired effect; 
b. A markedly diminished effect with continued use of the same amount of an opioid; 
*Note: This criterion is not considered to be met for those taking opioids solely under 
appropriate medical supervision. 
11. Withdrawal, as manifested by either of the following: 
a. The characteristic opioid withdrawal syndrome (refer to Criteria A and B of the criteria set 
for opioid withdrawal); 
b. Opioids (or a closely related substance) are taken to relieve or avoid withdrawal symptoms; 
12. The severity of OUD can span from mild to severe, and treatment varies depending on this severity.   
a. Mild: two to three criteria are met;  
b. Moderate: four to five criteria are met; 
c. Severe: six or more criteria are met.  
 *Adapted from DSM-5  
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1960s as maintenance therapy for moderate-severe OUD 3. It is also used to treat severe chronic 
pain. When used for OUD, methadone may only be dispensed through a Substance Abuse and 
Mental Health Service Administration (SAMHSA) certified opioid treatment program (OTP) 10. 
Typically, a patient becomes involved in an OTP—either inpatient or intensive outpatient—and 
is dispensed a daily dose of methadone determined to be appropriate for their prior opioid use by 
the medical director of the OTP. The patient is observed swallowing the methadone dose each 
day to ensure there is no diversion of medication. After a period of treatment stability, patients 
may be allowed to take doses of methadone at home but are still required to return to the OTP for 
regular follow up visits. One aspect of methadone treatment at OTPs that is problematic is that 
the medication is not technically prescribed by the OTP, but rather it is only dispensed. The 
methadone is also not reported to the state controlled substance registry. This means that outside 
providers cannot verify whether or not a patient is being treated with methadone at an OTP. 
According to a key informant, “this creates headaches because it provides incomplete clinical 
information that is essential to medical decision-making.” 
Extensive research supports the efficacy of methadone treatment. In fact, it is marginally 
more efficacious in treating OUD compared to buprenorphine 11. Methadone is the first line 
treatment of OUD in pregnant patients, as there is a long history of use and it has been found to 
be safe for mother and fetus 3. However, recent data now supports the use of buprenorphine 
during pregnancy. There are many limitations to the use of methadone. Its action as a full opioid 
agonist is a major concern, as the drug does have abuse potential and is more prone to cause 
lethal overdose due to respiratory depression when compared to buprenorphine. For this reason, 
methadone is a DEA Schedule II drug. Similar to other full agonists, chronic use of methadone 
can lead to hyperalgesia (abnormally heightened sensitivity to pain) in patients 11. Some studies 
have shown a “weak but significant risk” for cardiac arrhythmias, such as torsades de pointes, 
when taken as prescribed or in overdose at doses of up to 300 mg/day or above 16,11. 
Pathophysiology of these associated cardiac arrhythmias is not well-understood. In addition to 
the pharmacologic risks associated with potent full opioid agonists, there are regulatory and 
logistical constraints to providing methadone maintenance to patients with OUD.  These 
probably constitute the largest obstacle to more widespread use of methadone for OUD.  By law, 
treatment with methadone may only be obtained at an OTP under direct supervision.   
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The newer drug, buprenorphine is a partial opioid agonist that was discovered in 1966 but 
has only been FDA approved in the United States for OUD since 2002 12. The drug is also 
approved to treat severe pain and has been approved in the US for this indication since 198512. 
Buprenorphine may be prescribed by any clinician who has undergone required training and 
obtained a waiver from SAMHSA, in OTPs, clinician’s offices, or other appropriate settings 11. 
Available formulations for the treatment of OUD include a sublingual tablet, sublingual or 
buccal film strips--with or without naloxone--and a long-acting implantable subdermal 
buprenorphine implant. The naloxone combination is used to prevent diversion of the drug. 
Naloxone has poor oral bioavailability and, if taken appropriately, only the buprenorphine 
component will be active. However, if the drug is injected, users will experience immediate 
opioid withdrawal as naloxone displaces buprenorphine or other opioids in the body from mu-
receptors. Studies have shown buprenorphine to be nearly as effective as methadone in treatment 
of moderate-severe OUD and current recommendations do not prefer methadone over 
buprenorphine 11. Buprenorphine is safer than methadone, as its partial opioid agonist activity 
decreases the risk for abuse potential and lethal overdose due to respiratory depression. 
Furthermore, a major advantage of buprenorphine is the increased access to treatment for 
patients in comparison to methadone.  
Naltrexone is a third option for treating OUD. In contrast to methadone and 
buprenorphine, naltrexone is a full opioid antagonist.  It has been approved for the treatment of 
OUD since 1984 11. Naltrexone is not DEA scheduled and may be prescribed by any clinician in 
any appropriate setting. It is also used for alcohol use disorder and weight loss. Formulations 
include daily oral dosing and monthly long-acting injectable naltrexone. Current guidelines 
recommend the use of naltrexone for mild OUD or for highly motivated patients 11. Unlike 
buprenorphine or methadone, a patient must abstain from opioid use for at least 7-10 days in 
order to prevent the very unpleasent symptoms of precipitated withdrawal. This is one reason 
why naltrexone is not used as much as buprenorphine or methadone. 
 
Prevalence of OUD 
OUD affects people of all races, socioeconomic backgrounds, and ages. Risk factors for 
developing OUD among patients prescribed opioid analgesics include younger age, more severe 
pain, co-occurring mental disorders, and prior history of substance use disorder 13. According to 
9 
 
 
the 2016 SAMHSA National Survey on Drug Use and Health (NSDUH), an estimated 11.8 
million people in the US misused opioids in the past year, “including 11.5 million pain reliever 
misusers and 948,000 heroin users.” Approximately 2.1 million people suffered from OUD in 
2016 13. The rate of past year opioid misuse in 2016 was highest among people aged 18-25, at 
7.3% of the population of that age group 13. According to the NSDUH, among the main reasons 
cited for abusing prescription opioids in all age groups, 62.3% of participants noted “relieving 
physical pain” as their main reason 13. In this same study, about half of participants obtained 
these medications from family or friends, whereas only 37.5% obtained their prescription 
through the medical system. 
Over 100 million Americans suffer from chronic pain, making it a healthcare problem 
that affects more people than diabetes, heart disease, and cancer combined 14. Some healthcare 
providers fear that chronic pain patients’ needs are being unmet due to “opiophobia,” an 
increasingly prevalent “phenomenon in which exaggerated concern about the risks associated 
with opioids prevent appropriate medical use of opioid analgesics”15. This can lead some chronic 
pain patients to seek relief outside the medical system, such as obtaining pain medications from 
friends or family, or trying illicit opioids for relief. Upon interviewing people who transitioned 
from abusing prescription opioids to heroin, it was noted that most users chose heroin due to its 
lower cost and easy availability 16. Some users also attributed it to their physicians being “less 
willing to prescribe opioids as well as to increased attention to the issue by law enforcement”16. 
Compared to heroin use rates from the 2014 and 2015 NSDUHs, heroin use in 2016 has 
remained stable 13. While heroin use remained stable, overdose rates from synthetic opioids (e.g. 
fentanyl and fentanyl analogues) doubled between 2015 and 201617. This is likely due to the 
influx of fentanyl and fentanyl analogues like carfentanil into the black market, specifically 
between July to December of 2016 in the Northeastern US18. Heroin users unwittingly use these 
chemicals and overdose, as fentanyl and carfentanil are exponentially more potent than heroin.  
 
Impact of Opioid Use Disorder 
According to the National Institute on Drug Abuse, as of March 2018, more than 115 
Americans die daily due to opioid overdose 1. This number does not take into account the 
number of patients that die or suffer from complications from intravenous drug use (IVDU), such 
as HIV/AIDS, hepatitis C, or other infectious sequelae of IVDU. Also, not included in this 
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statistic are the number of babies that suffer from neonatal abstinence syndrome due to maternal 
opioid use during pregnancy or die of prematurity secondary to maternal opioid use. The 
economic burden of the current US opioid epidemic is estimated by the CDC to be “$78.5 billion 
a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal 
justice involvement”1.  
Given the thousands of opioid overdoses and heavy economic burden of the opioid 
epidemic, President Donald Trump declared the opioid epidemic a “national public health 
emergency” on October 26th, 201719. This declaration allows the federal government to create 
temporary positions within the Department of Health and Human Services (HHS) to focus on the 
opioid crisis and, in theory, makes federal public health funding more accessible to states in 
need. Many public figures believe that this response is not sufficient, and they have criticized the 
federal government for not classifying the opioid epidemic as a “National Emergency” under the 
Stafford Act. This would unlock supplemental funds from the Federal Disaster Relief Fund to be 
used to fight the opioid epidemic, rather than redeploying funds from existing federal programs. 
Despite these criticisms, the declaration does emphasize the importance of improving access to 
care for those with OUD.  The declaration states that the federal government will work to 
“expand access for certain groups of patients to telemedicine for treating addiction; provide new 
flexibilities within HIV/AIDs programs…” and “announce a new policy to allow treatment at 
more facilities” 19. 
 
Barriers to Care  
A problematic finding from the 2016 NSDUH is that while 26 million people ages 12 and 
older were noted to have a “need for substance use treatment in the past year,”, only 1.4% of this 
population received any substance use treatment 13. That means that only, 360,000 patients have 
access to SUD care. Many patients who are dependent on prescription opioids and seeking 
treatment note a variety of barriers to access: high costs, limited access to facilities, and lack of 
information 20. These barriers are substantial. Relieving them will require a determined 
coordinated approach and systematic set of solutions.  These include the following: systems that 
ease financial burdens on patients; open communication between healthcare providers and 
patients in order to decrease stigma, promote education, and deter fear of being reprimanded and 
losing access to pharmacotherapy 21. Clinic-based interventions—such as naloxone prescription 
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and counseling on how to reverse overdose using naloxone for those prescribed chronic opioid 
therapy and access in the primary care setting to MAT—have the potential to reduce the 
occurrence of overdose related deaths 22. Despite MAT’s potential to produce improved patient 
outcomes, uptake of office-based MAT by physicians has been disappointing. Both patient and 
healthcare provider factors explain this. 
For patients, cost presents a significant barrier to accessing care for those with OUD. 
These costs are not simply limited to the actual cost of the medication but include the cost of 
physician visits, transportation, counseling services, lab testing, emergency detoxification, and 
ongoing service referrals by the prescribing physician. The extent of the coverage of these costs 
by insurance is widely variable. The Affordable Care Act (ACA) has included at least some level 
of services directed at Substance Use Disorders as a part of its Essential Health Benefits. 
Essential Health Benefits are a set of 10 categories that health insurance service plan must cover 
under the ACA. Commercial insurance coverage of OUD treatment depends on several factors 
including “medical necessity, whether medications are covered, if there is a required co-
payment, if buprenorphine is on the plan’s approved medication list” 23.  
ACA provisions have also broadened Medicaid coverage for adults and state capacity to 
address the opioid epidemic. Reports from the Kaiser Foundation indicate the Medicaid currently 
covers 38% of nonelderly adults with opioid addiction. A 2013 review of Medicaid Policies 
showed that 50 Medicaid programs have included buprenorphine-naloxone in their approved 
preferred drug lists. For those that are uninsured, access to affordable provisions of MAT 
depends on whether local community clinics offer these services in the first place. The out of 
pocket cost of a 30-day supply of buprenorphine-naloxone is approximately $150, but can 
increase to as much as $600 depending on the dose24. This cost can also vary greatly, depending 
on the drug prescribed (generic vs. brand, combo product vs. mono product, etc…). While 
insurance plans vary, insurance coverage of MAT for OUD generally imposes greater 
restrictions compared to MAT for alcohol use disorder 25. 
 
 Goals of Research  
The primary goal of this project will be to focus on a needs assessment evaluating the 
following question: How can MAT with buprenorphine be better incorporated into the primary 
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care setting, and what barriers exist in accomplishing this? “Primary care” will be defined 
following the definition of the American Academy of Family Physicians in Text Box 2.  
Text Box 2  
 
This evaluation will examine primary care clinics that have successfully incorporated 
MAT into practice to determine what barriers these clinics faced, how these barriers were 
overcome, and what factors led to the clinics’ success. These clinics are UNC Aycock Family 
Medicine and Piedmont Health Chapel Hill Community Health Clinic. This assessment will be 
done utilizing key informant interviews of MAT providers at the aforementioned clinics. A brief 
assessment will also be conducted of a primary care clinic that plans to incorporate MAT into 
their practice, Piedmont Health Prospect Hill Community Health Clinic. Key informant 
interviews will be conducted of providers at this clinic to evaluate expected barriers and to 
determine strategies to overcome these barriers.  
 
III. Methods 
Published Literature Review 
 A preliminary literature review was conducted to better understand the extent and scope 
of current research efforts being made regarding efficacious implementation of MAT into the 
primary care setting. Search engines that were used included: PubMed, Google Scholar, 
Cochrane Library, and EmBase. MeSH Terms used included the following:  
Primary care is that care provided by [clinicians] specifically trained for and skilled in 
comprehensive first contact and continuing care for persons with any undiagnosed sign, 
symptom, or health concern (the “undifferentiated” patient) not limited by problem origin 
(biological, behavioral, or social), organ system, or diagnosis.  
 Primary care includes health promotion, disease prevention, health maintenance, 
counseling, patient education, diagnosis and treatment of acute and chronic illnesses in a variety 
of health care settings (e.g. office, inpatient, critical care, long-term care, home care, day care, 
etc.). Primary care is performed and managed by a personal [clinician] often collaborating with 
other health professionals, and utilizing consultation or referral as appropriate. Primary care 
provides patient advocacy in the health care system to accomplish cost-effective care by 
coordination of health care services. Primary care promotes effective communication with 
patients and encourages the role of the patient as a partner in health care.26 
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1. Buprenorphine-naltrexone 
2. Suboxone 
3. Extended-release naltrexone 
4. Medication-assisted treatment 
5. Opioid use disorder 
6. Primary care 
7. Barriers  
8. Interdisciplinary management 
9. Addiction medicine 
10. Behavioral medicine 
11. Medication-assisted treatment 
12. Opiate substitution treatment 
13. Opioid partial agonists 
14. Opioid-related disorders 
15. Substance-related disorders  
 The literature review provided foundational knowledge regarding the pathophysiology, 
epidemiology, and treatment options of opioid-use disorder and the utilization of MAT. The 
literature review also revealed the feasibility of incorporating MAT into primary care and the 
barriers that exist to do so. A variety of implementation models were explored during the 
literature review, including the Office-Based Opioid Treatment (OBOT) model, Massachusetts 
nurse care manager model, Hub and Spokes model, and ED Initiation of OBOT model (Table 
1)27. See Table 2 for a summary of systematic reviews analyzed during the literature search. 
Quality of systematic reviews was analyzed utilizing AMSTAR bias tool (Appendix B).   
 
 Key Informant Interviews 
We identified 6 key informants and interviewed them during three separate interviews 
and an email questionnaire. Key informants were selected based on their expertise and 
experience using MAT in a primary care setting. These key informants were comprised of 
physicians (family medicine, internal medicine and addiction medicine, all practicing in primary 
care settings), social workers, and a care manager.  
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Interviews were loosely structured and were conducted by two researchers, with one 
facilitating the conversation with primarily predetermined questions and the other taking notes. 
Predetermined questions addressed MAT models of care, important factors to successfully 
establishing MAT care at the clinic and patient level, and barriers to incorporating MAT into the 
primary care setting as ascertained from the preliminary literature review (Appendix A). 
Additional questions were asked during the interview based on informant responses. One to three 
key informants were involved per interview, including at least one licensed or soon-to-be-
licensed MAT provider per clinic. Interview 1 involved a physician who has not yet incorporated 
MAT into his practice. Interviews 2 and 3 included two separate primary care clinics that utilize 
differing models to incorporate MAT into patient care. Audio recordings of these interviews 
were transcribed, analyzed, and summarized by each researcher following each interview. The 
email questionnaire was sent to two key informants at one primary care clinic that had not yet 
implemented MAT into their practice but had plans to begin doing so in the near future. Answers 
to each questionnaire were analyzed and summarized by each researcher following the collection 
of all responses. 
 
Intervention Mapping for Program Plan Development 
The ultimate goal of this publication is to develop a program plan for primary care clinics 
planning to incorporate medication assisted treatment into practice. In order to develop this 
program plan, the authors utilized the Intervention Mapping Protocol by Bartholomew et al 28. 
The Intervention Mapping website describes the protocol as “a planning approach that is based 
on using theory and evidence as foundations for taking an ecological approach to assessing and 
intervening in health problems and engendering community participation” 29.  The approach 
consists of six basic steps, involving conducting a needs assessment, creating logic models for 
both the problem and the proposed change, program production and evaluation (Table 3). The 
authors conducted the steps described in Table 3 to produce a program plan suitable for the target 
users.  
 
IV. Results 
 Literature Review Findings 
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Results from our literature search provided background knowledge to the authors 
regarding OUD and the use of MAT. As discussed above, the advantages and 
disadvantages of different models of care were reviewed 27. Two systematic reviews were 
examined during the literature search, a 2011 review by Amato et al and a 2017 review 
by Gowing et al 32, 33. Amato et al reviewed 35 randomized controlled trials and 
controlled clinical trials of patients with OUD to evaluate the effectiveness of 
psychotherapy plus agonist maintenance treatment versus agonist maintenance treatment 
alone 32. Agonist treatments utilized in the reviewed studies included methadone, 
buprenorphine, and LAAM. The authors found that adding psychosocial interventions to 
standard agonist maintenance treatment did not offer any statistically significant benefit, 
in terms of retention in treatment, abstinence from opioid use, compliance, and 
psychiatric symptoms. The primary limitations of this systematic review is that most of 
the studies reviewed were conducted at specialty treatment centers (as opposed to 
primary care clinics). This limitation is important, because it limits generalizability of the 
findings. Patients of an experienced addiction medicine provider at a specialty treatment 
center may not benefit from adding psychosocial interventions to medication treatment as 
much as patients at a primary care clinic.  
Gowing et al analyzed 27 randomized controlled trials of patients with OUD to 
evaluate whether there is a difference in treatment completion rates in patients treated 
with buprenorphine maintenance therapy versus methadone maintenance therapy 33. The 
review did not find statistically significant differences in days of treatment completed or 
rates of adverse effects between either therapy. Limitations of the systematic review 
included varying routes of administration and dosages of buprenorphine, selection bias 
and early cessation in a few studies, and a primarily male study population.  
 
Key Informant Themes 
Provider Awareness and Motivation  
Providers surveyed cited lack of general awareness regarding MAT, time 
constraints to receiving training for MAT, fear of negative patient outcomes, and 
lack of motivation as significant barriers to pursuing an MAT waiver. The need to 
treat chronic pain patients’ substance dependence is also something that was cited 
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as intimidating by the healthcare providers surveyed. Additionally, providers cited 
a general mistrust and wariness of a “fix-all” solution that buprenorphine has been 
marketed as because this is how opioids were marketed initially in the 1990s as 
the pharmacologic solution for chronic pain. In order to prescribe or dispense 
buprenorphine products in the treatment of OUD, clinicians are required to 
complete at least 8 hours of training (24 hours for advanced practice providers) 
and then apply for an MAT waiver 30. This training provides education about the 
drug and prescriber practices. Key informants that attended this training found it 
to be very informative for their practice.  
Medicine is a changing and imperfect science. Clinicians are constantly 
facing the challenging task of staying up to date with advances in treatment 
options. This is especially true in primary care clinics where providers are 
managing large volumes of patients with many comorbidities, with short visit 
times and limited support resources. As the opioid crisis reaches monumental 
heights—enough so to be labeled as a national public health emergency—our key 
informants see the incorporation of treatment options such as MAT as an 
inevitable move in the primary care sphere. One key informant likened the 
apprehension of addressing OUD in the primary care setting to the treatment of 
mental health disorders such as depression. OUD, similarly to depression, often 
necessitates treatment with medication as well as adjuvant psychotherapy in order 
to be successful.  
Identifying a lead provider who is familiar with the waiver training and the 
complexities of prescribing buprenorphine to high-risk patients is crucial to 
implementing this shift in the primary care setting. The providers interviewed 
found the waiver training extremely effective, but also cited having colleagues 
experienced in MAT as a valuable resource. For healthcare providers that may not 
have colleagues within their clinic that are experienced with MAT, key 
informants cited the importance of seeking local resources to guide MAT 
implementation efforts. Within the Chapel Hill/Carrboro community, the UNC 
ECHO for MAT project was cited as resource that provides such support. UNC 
ECHO for MAT is a project that partners with clinics to build internal capacity to 
Commented [CPR10]: Wariness of “fix all” solutions is 
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incorporate MAT within the outpatient setting. UNC ECHO utilizes a multi-
faceted approach to develop individualized clinic plans to train staff internally and 
to also build an external community support network to provide greater patient 
access to referrals and community resources 31.  
 In addition to utilizing knowledgeable and experienced MAT providers, 
having providers passionate about the treatment of OUD with buprenorphine is 
crucial. As our key informants mentioned, patients with OUD are complex and 
sometimes “difficult.”  If a provider is not highly motivated and especially 
interested in working with such a population, successful incorporation of MAT 
into their practice’s standard set of services is unlikely to occur.  
 
Stigma  
 A key component to increasing motivation to treat such patients is stigma 
reduction regarding OUD. The issue of stigma was repeatedly noted by our key 
informants as a significant barrier to be overcome. Key informants recollect that 
many providers at their respective clinics had concerns that implementing an 
MAT program would bring “difficult patients”. According to our key informants, 
providers and staff at the clinic have expressed concerns that “they don’t want 
these patients in the waiting room” and “worry that the practice will become a 
methadone clinic,” highlighting the generalized way in which many people view 
addiction, OUD, and chronic pain patients. Providers surveyed noted concern that 
once they become MAT trained that their patient panel will consist entirely of this 
type of patient population and the challenges that come with treating a patient that 
has a diagnosis of substance use disorder. These challenges were cited as non-
compliance, mistrust, and “drug-seeking” behaviors. 
One key informant compared patients with OUD to patients with any other 
chronic illness. For instance, treating patients with diabetes requires addressing 
issues such as medication and diet noncompliance and the often-psychosocial 
factors behind such noncompliance.  Key informants emphasized the necessity of 
reframing addiction as a chronic neurologic illness, rather than a moral failing. 
Physiologically, opioids change the reward system of the brain and lead to “side-
Commented [CPR11]: Key informants is no longer 
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effects” such as “drug-seeking” behavior. Key informants emphasized the need to 
think of the negative behaviors of those with OUD as a manifestation of their 
chronic neurological illness. Thinking of substance use disorders in this way 
allows healthcare providers to have healthier therapeutic relationships with their 
patients in which they are able to establish boundaries, expectations, and not feel 
personally affected by non-compliance. Key informants emphasized that MAT 
with buprenorphine may promote remodeling of the brain through reduction in 
cravings which allows for the establishment of normal reward circuits. Unlike 
methadone, people on buprenorphine have minimal functional limitations, 
according to one key informant. Ultimately, according to a key informant, MAT 
with buprenorphine can allow patients to reintegrate into society as a productive 
and functional citizen.  
 
Appropriate Patients and Referral Structures  
Due to the high prevalence of OUD, MAT programs are extremely 
popular in the community. Invariably, most primary care clinics serve patients 
that are suffering from OUD, whether this condition is being directly treated or 
not. According to a key informant at a large area family medicine clinic, providers 
are “seeing these patients anyway.” Key informants recommended that providers 
begin incorporating MAT into their care by identifying which of their current 
patients may benefit from MAT. Starting with patients with which a clinician has 
already built rapport allows for a more seamless transition to providing MAT.  
When accepting new patients who have a desire to try MAT, key 
informants emphasized the capacity that clinicians have in choosing the patients 
that they deem appropriate for MAT therapy in the primary care setting. Key 
informants cited patient motivation to recover and complexity of a potential 
patient’s substance use disorder as two of the most influential factors as to 
whether a patient is accepted into their programs. For a novice MAT provider, it 
is recommended to have specific criteria for selecting patients that the provider 
feels could be safely managed on MAT. Patient motivation may be a factor that is 
difficult to quantify. Having a screening and application process may be useful in 
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discerning patients that have the self-initiative. Also, patients may have to wait 
weeks to months for an MAT appointment. This wait often “weeds out” less 
motivated patients, according to our key informants. However one key informant 
points out that “this “weeding-out” approach implicitly has more risk of patient 
harm and death due to delay in treatment.”  
One aspect of providing MAT in primary care that our key informants 
highlighted as especially important is a practice having the ability to discern 
which patients are appropriate to accept into the program and which patients 
necessitate referral to a higher level of care. Just as with patients with other 
chronic illnesses, Key informants emphasized the ability that MAT providers 
have to refer patients with OUD to higher levels of care if needed. 
 
Adequate Support Staff 
Key informants varied in terms of the necessities of support staff which 
they found to be adequate in establishing and maintaining an MAT program 
within the primary care setting. Generally, key informants found that staff 
education prior to introducing MAT into the primary care setting is important. 
Explaining to clinic staff the basics of MAT and relevant protocols (and 
modifications) is crucial.  Emphasizing the need to treat these patients in a 
humane way is critical and sharing success stories of patients who have benefited 
from MAT may be helpful, according to key informants.  
 Having an in-house social worker within a primary care clinic was cited 
as an invaluable resource to implementing MAT. Responsibilities of an MAT 
social worker or psychologist would include conducting screening interviews for 
patients interested in beginning MAT, conducting brief follow-up therapy as 
needed, and disseminating resources to patients to save MAT providers time. An 
in-clinic social worker or psychologist allows MAT prescribers to ultimately see 
more patients, according to our key informants.  Having established adjuvant 
behavioral health resources (whether located in-clinic or nearby) was cited as an 
essential component to address co-occurring mental health disorders in patients 
with OUD. An in-house social worker or psychologist is able to not only assist 
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with connecting patients to behavioral health resources, but also in handing-off 
key information regarding patient history and medical care to the MAT provider 
to allow for seamless and informed continuity of care.  
 
Institutional Buy-In/Cost  
On an institutional level, “buy in” is an essential component to the 
incorporation of MAT in the primary care setting. Buy-in is not only essential at 
the level of high-level administration, but also for physicians working at the clinic 
and support staff. Though many community practices are not “profit driven,” such 
practices do operate on very tight budget margins.  MAT in primary care must be 
implemented in a fashion that does undermine already tenuous fiscal 
sustainability. A financial model that demonstrates program sustainability, and 
profitability to a certain extent (at minimum, no sunken costs) is an important 
aspect to consider when vying for institutional buy-in. Depending on the access to 
insurance of the MAT patient population at a specific institution, organizations 
may need to consider a plan in terms of absorbing potential costs from services 
that uninsured patients may incur. 
 
Program Planning Steps  
Logic Model of OUD, Plan Objectives, and Logic Model of the Change 
As mentioned previously, OUD is a widespread problem that affects 
various populations and impacts not only the user’s quality of life, but also the 
overall health of the community. A logic model for the problem of OUD is 
included in Appendix C. While the entire United States is currently entrenched in 
an epidemic of opioid use and dependence, this program plan is most applicable 
to the treatment of adult patients in primary care practices in the Piedmont region 
of North Carolina. All of our key informants practice in this area and 
recommendations are based on this environmental/population context. Other 
regions of the state and country have different populations and environmental 
determinants that may make this program plan less effective.  
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The ultimate goal of this program plan is to incorporate MAT into primary 
care practice; in effect, reaching more patients suffering from OUD with an 
evidence-based treatment method and making treatment more easily obtainable 
and affordable. Secondary outcomes of this plan are: increasing the number of 
patients with OUD in remission, decreasing the number of lower acuity patients 
seen by specialty practices (e.g. psychiatry), decreasing the cost of care by 
offering treatment by primary care providers, decreasing negative health 
outcomes of untreated OUD (e.g. needle-borne illnesses, bacterial complications, 
cardiac complications, mental health issues, etc.…), among others. Expected 
outcomes of the program plan are described in Table 4. 
In order to accomplish the primary goal, attain the desired secondary 
outcomes and observe the expected outcomes of this program plan, it is necessary 
that change occur at different points in the healthcare system. The performance 
objectives for the change outcomes are broken down by ecological level: personal 
(patient), interpersonal, organizational (the participating healthcare practice), 
community, and societal. The term “performance objectives” refers to what 
specifically needs to be done in order for the expected outcomes to be met. These 
performance objectives are described in Table 4. The italicized text in Table 4 
refers to the ecological levels, outcomes and objectives highlighted as most 
relevant to this program plan. The performance objectives listed in Table 4 are not 
all-inclusive, and certainly additional factors are patient dependent.  
A logic model for the proposed change is included in Appendix D. Key 
components of the logic model include change objectives, behavioral and 
environmental change outcomes, and the desired health problem outcome. 
Change objectives include treatment co-occurring mental and physical health 
conditions (including chronic pain), prescription monitoring and appropriate 
prescribing, education, among other factors (See Appendix D).  Behavioral 
change outcomes include preventing initiation and abstinence of substance abuse, 
among others. Environmental change outcomes occur on the personal, community 
and societal levels. Personal-level change outcomes include healthier, drug-free 
relationships. Community-level outcomes include safe living spaces, drug-free 
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workplace, among others. Societal-level outcomes include improved 
socioeconomic status and freedom from discrimination. The overarching health 
problem outcome is remission from OUD.  
 
Program Plan Design, Production and Implementation Plan 
 Different models exist of MAT implementation in the primary care 
setting, as discussed previously (see Table 1). The institutions at which our key 
informants practice did not specifically model their MAT prescribing around an 
existing model of care. One of the clinics that had incorporated MAT into their 
workflow functions similar to the Office Based Opioid Treatment model with the 
assistance of a social worker care manager for screening interviews and 
psychotherapy. The other clinic that has incorporated MAT into practice also 
functions similar to the Office Based Opioid Treatment model, although the MAT 
prescriber at this practice is not a primary care physician but instead an addiction 
medicine specialist practicing at a primary care office. These differences highlight 
the idea that there are various methods to tailor the specific model by which MAT 
is offered at an individual clinic to the intricacies of that specific clinic. 
Additional important themes in offering MAT in the primary care setting noted by 
our key informants are discussed above in the section “Key Informant 
Interview/Questionnaire Themes.” 
 Potential users of this program plan include primary care practices treating 
adults with OUD in which at least one provider will offer MAT. Ideally, a 
practice would have multiple providers offering MAT. However, based on the 
success of one of the clinics examined in which only one provider offers MAT, 
we propose that it is possible to provide quality care to patients with OUD as long 
as at least one provider offers MAT and is supported by the clinic. Desired 
outcomes and performance objectives for program use are italicized in Table 4. 
Prior to embarking on any of the following recommended steps (Table 5) for 
incorporating MAT into practice in a primary care office, an interested practice 
should develop a financial model addressing how MAT will be offered in a cost-
effective manner. As previously discussed, many patients who need MAT are 
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either underinsured, uninsured, or otherwise financially burdened. The practice 
will need to determine how it will absorb the costs of such patients. Providing 
MAT need not be economically profitable, but offering such care should not be 
significantly burdensome or costly. This paper will not address a detailed 
economic strategy for implementing MAT effectively, as that is beyond the scope 
of this practice transformation model.  
 Based on the considerations of providing MAT in the primary care setting 
highlighted by our key informants and background research on the topic, the 
authors recommends that a practice base their MAT practice on the Office Based 
Treatment Model and tailor treatment to unique clinic and patient needs (Table 1). 
The practice should also strongly consider hiring a social worker or psychologist, 
to provide in-house psychological services and screening interviews. If no 
behavioral health professional will be available to patients at the clinic, a 
relationship must exist between the MAT provider and a local behavioral health 
professional such that patients can be easily referred for timely service as needed. 
This aspect of our proposed practice transformation model is based on the 
recommendation of key informants to have easily accessible psychological 
services. As previously mentioned, the finding by Amato et al that psychosocial 
interventions do not add a statistically significant benefit to medication treatment 
is not generalizable to primary care clinics.  
 In order for a clinic to effectively implement MAT into its workflow, it 
is critical that potential barriers be addressed prior to providers beginning to offer 
MAT. To accomplish this, the first step a practice should take would be to provide 
an in-house informational session for providers to learn about MAT and OUD. 
This training would address the following issues: 
1. Increase provider awareness of MAT for OUD and its application in the 
primary care setting.  
2. Review the epidemiology and pathophysiology of OUD and how MAT 
helps.  
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3. Discuss the types of patients suitable for MAT and factors to consider 
before accepting a new MAT patient, such as medical/psychiatric 
comorbidities, polysubstance use, support systems and motivation.  
4. Explain that MAT is not a “quick-fix” solution, but rather an evidence-
based treatment that works alongside individual or group psychotherapy to 
increase chances of remission from OUD.  
5. Discuss potential benefits for patients and success stories.  
6. Point out community resources for MAT providers and patients, such as 
the UNC ECHO Clinic.  
7. Discuss all available treatment options for OUD and provide information 
on where to refer if a patient requires a higher level of treatment.  
8. Explain the steps and requirements of MAT DATA-2000 waiver training.  
9. Address concerns that providers may have about offering MAT or 
working in a clinic that offers MAT.  
Interested providers would then proceed to become waiver trained and 
certified to begin providing treatment with MAT. Ideally, the buprenorphine 
waiver training will be offered in-house and paid for by the practice, to alleviate 
the perception some providers have that waiver training is time-intensive and 
expensive. Prior to beginning to offer MAT to patients, providers should review 
their current patients and determine which patients may be suitable for MAT. The 
practice should determine whether or not they would like to accept new patients 
for MAT. If the practice will accept new patients, the next step would be to 
develop a screening process for identifying appropriate patients. This will be 
provider/practice dependent, but general factors for consideration include patient 
motivation for sobriety, prior treatments, comorbidities or other substance use, 
and patient support system.  
In addition to offering an informational session for providers, before 
incorporating MAT into care a practice should offer an in-house training for staff 
members (medical assistants, nurses, etc.…). This training should accomplish the 
following objectives: 
1. Review the basics of OUD.  
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2. Address stigma and potential biases about patients with substance-use 
disorders.  
3. Explain the function of MAT and how it will be provided in the clinic.  
4. Discuss any potential changes that may occur to the daily functioning of 
the clinic.  
5. Address concerns that staff may have.  
After all employees at the clinic have been educated and concerns have 
been addressed, current patients deemed appropriate may be offered MAT for 
OUD. If deemed appropriate by the clinic/providers, new patients may be 
accepted for MAT. To ensure quality care and efficiency, the clinic should 
periodically evaluate the effectiveness of their MAT program and adjust as 
necessary.  
 
Program Evaluation Methods 
To evaluate the effectiveness of an MAT program, a clinic should 
periodically review its outcomes and processes in a standardized and organized 
manner. This is most effectively accomplished by providing all healthcare 
providers and staff involved in the MAT program a survey with specific 
questions. A separate survey should be provided to MAT providers and support 
staff, as different issues are faced by each group. The clinic should write their 
own survey questions to address practice-specific issues, but the following 
indicators should be addressed: 
1. Number of patients receiving MAT 
2. Patient success  
a. Abstinence from opioid use, as measured by urine drug screen 
b. Compliance with buprenorphine treatment, as measured by urine 
drug screen 
c. Involvement in treatment, as measured by attendance rate for 
medication-management appointments and for behavioral health 
appointments  
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d. Patient well-being, measured by provider perception, patient self-
report, patient employment status  
3. Provider effectiveness, success and barriers  
a. Number of MAT visits per evaluation period 
b. Estimated or calculated length of average MAT visit  
c. Provider perception of success  
d. Provider report of barriers faced  
4. Staff perception of success and barriers 
In addition to the above indicators of success, the practice should also 
evaluate the economic health of their program and determine if any changes are 
necessary. This evaluation should take place at least annually.  
 
V. Summary and Implications  
 The utilization of MAT with buprenorphine in combination with behavioral health 
services is an evidence-based approach to treating OUD. The integration of this treatment 
modality in the primary care setting would allow it to become more accessible to patients. In 
order to establish MAT with buprenorphine in the primary care setting, a variety of factors must 
be addressed. These factors include but are not limited to: institutional buy-in, appropriate 
patient referral structures, provider motivation and awareness, adequate support staff, stigma, 
and more. Practice transformation is always complex and following the aforementioned practice 
transformation model is not expected to be an easy process; however, the proposed model aims 
to break down the complexity of OUD into pieces that can be considered and addressed in a 
stepwise fashion. The transformation model describes a systematic framework for addressing 
these factors and implementing MAT into a primary care practice workflow, provided that 
important resource constraints can be overcome. 
One potential issue that clinics may face when implementing an MAT program following 
the above practice transformation model is creating a model that is economically feasible (i.e. no 
sunken costs) for the practice. As previously mentioned, discussion of such a model is beyond 
the scope of this paper, but an adequate economic model will consider potential insurance 
reimbursement for services and the potential economic implications of providing care to 
underinsured patients. Another barrier that practices should anticipate facing is that prevailing 
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payment mechanisms to resource and reimburse clinics for in-house behavioral medicine are 
often inadequate. In the case that this is an issue, practices may consider developing a 
relationship with a nearby behavioral health provider such that timely referrals for services can 
be made in lieu of having in-house services. Implementing any kind of institutional change, such 
as creating an MAT program, is a process that must be repeatedly evaluated in order to continue 
successfully. The importance of periodic program review using the proposed program evaluation 
methods should not be underestimated. Topics reviewed in such an evaluation should at a 
minimum include both patient and provider outcomes (perceived and objective), as well as staff 
perception of the program.  
There exist many potential implications for patients and practices when incorporating 
MAT with buprenorphine into the primary care setting. Obviously, the anticipated outcome is 
improved patient care and remission of OUD. However, our key informants noted that many 
patients treated with MAT in the primary care setting benefit beyond treatment of their OUD. 
One hope in providing care in a primary care clinic is that patients will interface more often with 
the healthcare system and have other chronic care or preventative health measures addressed at 
their visits. A worry voiced by a key informant is that prescribing buprenorphine in the primary 
care setting may lead to diversion of the drug. However, if diversion is an issue when prescribing 
buprenorphine, it is an even larger issue when prescribing opioids for pain management in the 
primary care setting, which is done much more often and with medications that are potentially 
more dangerous. The issue of diversion is controversial, but is an important topic for further 
research.  
Future research into treatment of OUD in the primary care setting is necessary to 
continue to improve patient outcomes and encourage the development of sustainable models of 
care. Suggested areas of research include the use of telemedicine for MAT maintenance visits, a 
comparison of patient outcomes among different MAT models, management of patients with 
OUD and concomitant chronic pain disorders, and the use and efficacy of longer-term 
medication formulations (e.g. implantable and injectable buprenorphine). In addition to the 
necessity of further research into this ever-relevant area of medicine, policy changes are needed 
at the national and private levels to ensure that patients in need of services can access care. As 
previously discussed, many have criticized President Donald Trump’s designation of the US 
opioid crisis as a “national public health emergency” as insufficient. Reclassifying the crisis as a 
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“National Emergency” under the Stafford Act would allow additional funds to be utilized, rather 
than reallocating funds from existing federal programs. Changes in insurance reimbursement for 
MAT for OUD that decrease barriers to the use of such medications as buprenorphine would also 
be immensely helpful for patients. Ideally, uninsured and underinsured patients would be able to 
access care and medications at a community clinic. In order for this to be possible, additional 
funding needs to be available for clinics offering such services. This is a very important area of 
future research and policy change.  
 
VI. References 
1. Opioid overdose crisis, Revised March 18. Available at: 
https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis 
2. Medication and Counseling Treatment | SAMHSA - Substance Abuse and Mental Health 
Services Administration. Available at: https://www.samhsa.gov/medication-assisted-
treatment/treatment#medications-used-in-mat. Accessed April 8, 2018. 
3. Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, 
screening, assessment, and diagnosis - UpToDate. Available at: 
https://www.uptodate.com/contents/opioid-use-disorder-epidemiology-pharmacology-clinical-
manifestations-course-screening-assessment-and-diagnosis?source=history_widget. Accessed 
April 8, 2018. 
4. A Brief History of Opioids. Available at: http://www.theatlantic.com/sponsored/purdue-
health/a-brief-history-of-opioids/184/. Accessed April 8, 2018. 
5. Opioid history: From “wonder drug” to abuse epidemic - CNN. Available at: 
https://www.cnn.com/2016/05/12/health/opioid-addiction-history/index.html. Accessed April 8, 
2018. 
6. Lanser P, Gesell S. Pain management: the fifth vital sign. Healthc. Benchmarks 
2001;8(6):68-70, 62. 
7. Opioid Epidemic - The Role of Pharmaceutical Companies in the Opioid Epidemic. 
Available at: https://www.addictions.com/opiate/the-role-of-pharmaceutical-companies-in-the-
opioid-epidemic/. Accessed April 8, 2018. 
29 
 
 
8. Opioid Agonists, Partial Agonists, Antagonists: Oh My! Available at: 
http://www.pharmacytimes.com/contributor/jeffrey-fudin/2018/01/opioid-agonists-partial-
agonists-antagonists-oh-my. Accessed April 8, 2018. 
9. Vanderah, T. W. (2010). Delta and kappa opioid receptors as suitable drug targets for 
pain. The Clinical Journal of Pain, 26 Suppl 10, S10–5. doi:10.1097/AJP.0b013e3181c49e3a 
10. Methadone | SAMHSA - Substance Abuse and Mental Health Services Administration. 
Available at: https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone. 
Accessed April 8, 2018. 
11. UpToDate. Available at: https://www.uptodate.com/contents/pharmacotherapy-for-
opioid-use-
disorder?search=methadone%20to%20suboxone&source=search_result&selectedTitle=1~123&u
sage_type=default&display_rank=1. Accessed April 8, 2018. 
12. Campbell ND, Lovell AM. The history of the development of buprenorphine as an 
addiction therapeutic. Ann. N. Y. Acad. Sci. 2012;1248:124-139. doi:10.1111/j.1749-
6632.2011.06352.x. 
13. Ahrnsbrak R, Bose J, Hedden SL, Lipari RN, Park-Lee E. Key Substance Use and  
Mental Health Indicators in the United States:  Results from the 2016 National Survey on Drug 
Use and Health. Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance 
Abuse and Mental Health Services Administration.: Substance Abuse and Mental Health 
Services Administration; 2017. 
14. Ives, T. (2017). Update On Pain Management Powerpoint 
15. Keller CE, Ashrafioun L, Neumann AM, Van Klein J, Fox CH, Blondell RD. Practices, 
perceptions, and concerns of primary care physicians about opioid dependence associated with 
the treatment of chronic pain.Subst. Abus. 2012;33(2):103-113. 
doi:10.1080/08897077.2011.630944. 
16. Compton WM, Jones CM, Baldwin GT. Relationship between Nonmedical Prescription-
Opioid Use and Heroin Use. N. Engl. J. Med. 2016;374(2):154-163. 
doi:10.1056/NEJMra1508490. 
17. Products - Data Briefs - Number 294 - December 2017. Available at: 
https://www.cdc.gov/nchs/products/databriefs/db294.htm. Accessed April 8, 2018. 
30 
 
 
18. O’Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths Involving 
Fentanyl, Fentanyl Analogs, and U-47700 - 10 States, July-December 2016. MMWR Morb 
Mortal Wkly Rep 2017;66(43):1197-1202. doi:10.15585/mmwr.mm6643e1. 
19. Donald Trump declares public health emergency over opioid crisis. Here’s what that 
means | PolitiFact. Available at: http://www.politifact.com/truth-o-
meter/article/2017/oct/30/opioid-epidemic-united-states-and-trump-administra/. Accessed April 
8, 2018. 
20. Mars SG, Bourgois P, Karandinos G, Montero F, Ciccarone D. “Every ‘never’ I ever said 
came true”: transitions from opioid pills to heroin injecting. Int. J. Drug Policy 2014;25(2):257-
266. doi:10.1016/j.drugpo.2013.10.004. 
21. Alford DP. Opioid Prescribing for Chronic Pain--Achieving the Right Balance through 
Education. N. Engl. J. Med. 2016;374(4):301-303. doi:10.1056/NEJMp1512932. 
22. Moore C, Lloyd G, Oretti R, Russell I, Snooks H. Paramedic-supplied “Take Home” 
Naloxone: protocol for cluster randomised feasibility study. BMJ Open 2014;4(3):e004712. 
doi:10.1136/bmjopen-2013-004712. 
23. Insurance and Payments | SAMHSA - Substance Abuse and Mental Health Services 
Administration. Available at: https://www.samhsa.gov/medication-assisted-
treatment/treatment/insurance-payments. Accessed September 8, 2018. 
24. Suboxone Prices, Coupons & Patient Assistance Programs - Drugs.com. Available at: 
https://www.drugs.com/price-guide/suboxone. Accessed September 8, 2018. 
25. Coverage of Substance-Use Disorder Treatments in Marketplace Plans in Six Cities. 
Urban Institute; June 2016. Available at: 
https://www.urban.org/sites/default/files/publication/81856/2000838-Coverage-of-Substance-
Use-Disorder-Treatments-in-Marketplace-Plans-in-Six-Cities.pdf. Accessed August 9, 2018.  
26. Primary Care. Available at: https://www.aafp.org/about/policies/all/primary-care.html. 
Accessed April 8, 2018. 
27. Chou R, Korthuis PT, Weimer M, et al. Medication-Assisted Treatment Models of Care 
for Opioid Use Disorder in Primary Care Settings. Rockville (MD): Agency for Healthcare 
Research and Quality (US); 2016. 
28.  Bartholemew et al (2016). Planning health promotion programs: An Intervention 
Mapping approach (4th ed). Hoboken, NJ: Wiley. 
31 
 
 
29. Intervention Mapping. Available at: https://interventionmapping.com/. Accessed August 
17, 2018.  
30. Buprenorphine Waiver Management | SAMHSA - Substance Abuse and Mental Health 
Services Administration. Available at: https://www.samhsa.gov/programs-
campaigns/medication-assisted-treatment/training-materials-resources/buprenorphine-waiver. 
Accessed September 8, 2018. 
31. UNC ECHO. Available at: https://echo.unc.edu/. Accessed September 8, 2018. 
32. Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance 
treatments versus agonist maintenance treatments alone for treatment of opioid dependence. 
Cochrane Database Syst Rev. 2011(10):CD004147. PMID: 21975742. 
33. Gowing, L., Ali, R., White, J.M., Mbewe, D. (2017) Buprenorphine for managing opioid 
withdrawal (Review). Cochrane Database of Systematic Reviews, Issue 2. Art No.: CD002025. 
doi: 10.1002/14651858.CD002025.pub5 
34. Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid  
Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. 
HHS Publication No. (SMA) 12-4214.  Rockville, MD: Substance Abuse and Mental  Health 
Services Administration, 2005. 
35. March 2012 / SAMHSA-HRSA. Available at: https://www.integration.samhsa.gov/about-
us/esolutions-newsletter/march-2012. Accessed April 8, 2018. 
36. Potter JS, Marino EN, Hillhouse MP, et al. Buprenorphine/naloxone and methadone 
maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from 
starting treatment with agonist replacement therapies (START). J. Stud. Alcohol Drugs 
2013;74(4):605-613. doi:10.15288/jsad.2013.74.605. 
37. Protocol T. For Opioid Addiction in  Opioid Treatment Programs. Available at: 
https://www.medicaid.gov/federal-policy-guidance/downloads/cib-07-11-2014.pdf   
 
 
VII. Tables  
 
Table 1. Overview of select MAT models of care for OUD in primary care  
Model Summary Components 
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Pharmacotherapy    Education/Outreach     Coordination of care        Psychosocial              Other 
OBOT (Office 
Based Opioid 
Treatment) 
Buprenorphine 
prescribed by 
PCPs who 
complete DATA 
2000 waiver 
training 
Primarily 
buprenorphine/n
aloxone 
Not a major 
component; 
Provider Clinical 
Support Service 
for MAT 
available to 
mentor primary 
care providers 
A non-physician 
clinic staff member 
sometimes used to 
coordinate MAT 
prescribing and 
integration with 
primary and mental 
health care. 
Physician, 
psychologist, 
social worker 
or other 
counseling at 
least monthly; 
Other 
psychosocial 
services vary, 
including 
integrated 
CBT and 
motivational 
enhancement 
therapy; some 
psychosocial 
services off-
site. 
___ 
Massachusetts 
nurse care 
manager  
A primary care–
based model that 
teams nurse care 
managers with 
primary care 
physicians; nurse 
care managers 
generally perform 
initial screening, 
intake, education, 
observed/support
s induction, 
follow-up, 
maintenance, 
stabilization, and 
medical 
management with 
the physician and 
team 
Primarily 
buprenorphine– 
naloxone, with 
recent addition 
of extended-
release 
naltrexone 
A training 
program exists to 
get more 
physicians 
(especially 
residents) and 
faculty on board. 
The Department 
of Public Health 
trains staff on 
best practices. 
Nurse care 
managers receive 
8 h of training in 
MAT, shadowing 
in model MAT 
site, site visits, e-
mail and 
telephone 
support, case 
review, quarterly 
training, and an 
addiction 
listserv. 
Nurse care managers 
(registered nurses or 
family NPs) manage 
100 to 125 patients 
alongside primary 
care clinicians, with 
assistance from a 
medical assistant. 
Alternatively, care 
partners (usually 
persons with a 
master’s degree) assist 
the primary care staff 
with screening, brief 
intervention, and 
referral to treatment. 
Psychological 
services are 
integrated on-
site or nearby 
Patients who 
require a higher 
level of care can 
be expedited into 
an OTP, assistance 
with transfers of 
care, and day-
support programs 
Hub and Spokes Centralized 
intake and initial 
management 
(buprenorphine 
induction) at 
“hub”; patients 
are then 
connected to 
“spokes” in the 
community for 
ongoing 
management 
Primarily 
buprenorphine– 
naloxone 
Outreach to 
prescribers in the 
community to 
increase the 
number of 
buprenorphine-
waivered 
physicians 
Coordination/integrati
on between hub and 
spoke as well as 
within each primary 
care site spoke. 
Registered nurse 
clinician case 
manager and/or care 
connector (peer or 
behavioral health 
specialist) for 
coordination/integrati
on of care at spokes. 
Embedded in 
spoke sites, 
including 
social workers, 
counseling, 
and 
community 
health teams. 
Hubs provide 
consultative 
services and are 
available to 
manage clinically 
complex patients; 
support tapering of 
MAT; or prescribe 
methadone, if 
needed 
Commented [CPR14]:  
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ED Initiation of 
OBOT 
ED identification 
of OUD; 
buprenorphine– 
naloxone 
induction 
initiated in ED; 
coordination with 
OBOT, nurse 
with expertise in 
buprenorphine 
working in 
collaboration 
with PCP 
Buprenorphine– 
naloxone 
Not a major 
component 
OUD identified in ED 
and patients started on 
buprenorphine 
therapy and connected 
to ongoing OBOT 
provided by 
physicians and nurses 
for 10 wk, then 
transferred to office-
based ongoing 
maintenance 
treatment or 
detoxification. 
“Medical 
management” 
counseling 
visits with 
physician and 
nurse 
___ 
(Adapted from Chou R, Korthuis PT, Weimer M, et al. Medication-Assisted Treatment Models of Care for Opioid 
Use Disorder in Primary Care Settings. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016.) 
 
Table 2. Details of Systematic Reviews 
Author, 
year 
Purpose of 
review 
Number 
of 
included 
studies 
Population 
characteris
tics 
Intervention 
characteristi
cs 
Type
s of 
studi
es 
inclu
ded 
Methods 
for 
synthesizin
g results of 
primary 
studies 
Total 
number 
of 
patients 
Findings Limitations 
Amato, 
2011 
To evaluate the 
effectiveness of 
psychotherapy 
plus agonist 
maintenance 
treatment vs. 
standard 
treatment for 
opioid 
dependence 
35 OUD (drug 
of choice 
not 
specified); 
setting not 
described 
(appears 
mostly 
specialist 
centers); 
USA, 
Germany, 
Malaysia, 
China, 
Scotland 
Any 
psychosocial 
intervention 
plus any 
agonist vs. 
agonist 
treatment 
alone; 
medical 
interventions 
were 
methadone, 
buprenorphin
e, LAAM; 
models of 
care not 
described 
RCTs
, 
CCTs 
GRADE; 
meta-
analysis 
done 
4319 No 
significant 
advantage of 
adding 
psychosocial 
interventions 
for retention 
in treatment 
and at 
follow-up, 
abstinence 
from opiates 
during 
treatment or 
at follow-up, 
compliance, 
psychiatric 
symptoms, 
and 
depression. 
Also, no 
significant 
difference in 
outcomes 
comparing 
psychosocial 
approaches.  
Focused on 
effectiveness of 
psychotherapy 
interventions in 
addition to 
standard 
interventions; 
Setting not 
described 
(appears mostly 
specialist 
centers); 31 
studies in USA 
Gowing, 
2017 
Analyze if there 
is a significant 
difference 
between the 
number of days 
of treatment 
27 OUD due to 
heroin or 
other 
opioids; 
setting not 
described 
Buprenorphin
e 
maintenance 
vs. 
methadone; 
models of 
RCTs GRADE; 
meta-
analysis 
done 
3048 BUP and 
MET have 
similar 
potentials to 
alleviate 
opioid 
BUP routes of 
administration 
and doses 
varied; authors 
identified 
selection bias 
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completed and if 
there is a 
difference in the 
number of 
patients that 
complete 
treatment  if 
treated with 
buprenorphine or 
methadone 
care not 
described  
withdrawal 
symptoms, 
with neither 
treatment 
having 
significantly 
more adverse 
effects than 
the other. 
and early 
cessation as 
issues in three 
of the six 
studies;  review 
included a 
relatively small 
number of 
participants that 
were primarily 
male 
(Adapted from Chou R, Korthuis PT, Weimer M, et al. Medication-Assisted Treatment Models of Care for Opioid 
Use Disorder in Primary Care Settings. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016.) 
  
Table 3. Intervention Mapping Steps 
Step 1: Logic Model of the Problem ● Conduct a needs assessment to create logic model of problem 
● Describe context for intervention (population, setting, community) 
● State program goals 
Step 2: Program Outcomes/Objectives; 
Logic Model of Change 
● State expected outcomes for behavior/environment 
● Specify performance objectives for outcomes 
● Select determinants for outcomes 
● Create logic model of change 
Step 3: Program Design ● Generate program themes, components, scope, sequence 
● Choose theory- and evidence-based change methods 
● Select/design practical applications to deliver methods 
Step 4: Program Production ● Refine program structure 
● Prepare plans for program materials 
● Pretest, refine and produce materials 
Step 5: Program Implementation Plan ● Identify potential program users 
● State outcomes/performance objectives for program use 
● Design implementation interventions 
Step 6: Evaluation Plan ● Write effect and process evaluation questions 
● Develop indications and measures for assessment 
● Specify evaluation design 
● Complete evaluation plan 
(Adapted from Bartholemew et al (2016). Planning health promotion programs: An Intervention Mapping approach 
(4th ed). Hoboken, NJ: Wiley.) 
 
Table 4. Expected Outcomes and Performance Objectives of Program Plan 
Ecological Level Expected Outcomes Performance Objectives 
Personal behavioral Patients... 
● Abstain from recreational 
substance use 
● Engage in behaviors that 
Patients… 
● Make the decision to seek treatment for 
substance use disorder 
● Have transportation/access to treatment 
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promote their sobriety (e.g. 
individual/group therapy, 12-step 
program, etc…)  
● Take buprenorphine at 
prescribed dose and frequency  
center and pharmacy 
● Have the financial means/insurance to 
afford treatment 
● Avoid places, people and triggers that may 
lead them to engage in substance use 
● Have a support system that assists them in 
maintaining sobriety 
Interpersonal 
environmental 
● Intimate partners/family 
members support patients in 
abstaining from substance use 
and in adhering to buprenorphine 
treatment 
● Peers do not encourage substance 
use 
● Intimate partners/family members/peers do 
not use recreational substances  
Organizational 
environmental 
At healthcare facilities... 
● Policies, programs, and facilities 
exist to assist substance-
dependent people in achieving 
and maintaining sobriety 
At healthcare facilities… 
● MAT is offered at primary care clinics 
● Providers have been waiver-trained to 
provide buprenorphine treatment 
● A behavioral medicine specialist (e.g. 
social worker, psychologist, etc…) is 
available as needed (e.g. at the clinic, by 
referral, etc…) 
● Staff has been trained to assist substance-
dependent patients 
● Policies and procedures have been 
developed specifically for MAT at the 
clinic 
Community 
environmental 
● Care for substance use disorder 
is easily accessible to patients 
● Health ordinances encourage 
treatment of substance use 
disorders 
● Community groups exist that 
encourage sobriety (e.g. group 
therapy, 12-step groups) 
● Substance use disorder is not 
stigmatized, but instead viewed 
as a treatable illness 
● MAT is available at primary care clinics, 
as opposed to solely by specialty 
practitioners  
● Public transportation is easily accessible to 
transport patients to clinics offering 
treatment  
Societal 
environmental  
● Legislation, law enforcement and 
regulations encourage 
rehabilitation and treatment of 
substance use disorders 
● Resources are allocated for 
rehabilitation and treatment  
● Policies, programs, and facilities 
exist to assist substance-
● Funding is available for clinics offering 
MAT 
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dependent people in achieving 
and maintaining sobriety  
 
 Table 5. Program Steps 
Step 1 Develop a financial model describing:  
1). How a practice will absorb the costs of MAT for financially burdened patients 
2). How all aspects of care will be paid for without any sunken costs 
Step 2  1). Hire in-house social worker or psychologist  
OR 
2). Develop relationship with local behavioral health professional such that patients can obtain 
services in a timely manner.  
Step 3 Host in-house information session for providers discussing MAT and OUD 
Step 4 Host in-house buprenorphine DATA 2000 waiver training session for interested providers 
Step 5 Potential MAT providers review current patients and determine which may benefit from MAT 
Step 6 Practice/providers determine if new patient will be accepted for MAT treatment. If so: 
1). Develop screening process for determining which patients will be accepted.  
2). Determine who will conduct screening (behavioral health provider or MAT provider) 
Step 7 Host in-house informational session for support staff discussing OUD, MAT and potential 
changes in clinic functioning  
Step 8 1). Providers begin to offer MAT to current patients deemed appropriate 
AND 
2). Begin accepting new patients for MAT, at clinic/provider discretion 
Step 9 Clinic periodically evaluates effectiveness of its MAT program and makes adjustments to 
workflow as necessary 
 
 
 
VIII. Appendices 
 
Appendix A. Questions for Key Informants 
Clinic Perspective Interview Questions 
Has implemented MAT 1. How and when was MAT implemented at this clinic? 
2. What models did this clinic consider in the early stages? 
3. What model does this clinic follow? 
4. What were the barriers to implementing MAT at this clinic? 
5. How did the clinic overcome these barriers (if able)? 
6. What were some factors that contributed to the clinic’s success? 
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7. In addition to the SAMHSA DATA 2000 waiver requirement to be able to prescribe 
buprenorphine, are there any additional requirements to prescribe at this clinic? 
8. Have there been any barriers to providers becoming licensed to prescribe buprenorphine?  
9. What do you think is the biggest reason providers choose to/not to become licensed? 
10. Have you noticed stigma around MAT (among providers, staff or other patients) to be an issue 
at the clinic? 
11. What is the biggest strategic barrier to incorporating MAT patients into this clinic? 
12. How is insurance coverage for these services? 
13. What have the results been like for patients at this clinic? 
14. Are there restrictions on the types of patients accepted by the clinic (e.g. no psychiatric 
comorbidities, only OUD, etc…)?  
15. What feedback have you received from providers regarding implementing MAT at the clinic? 
16. What behavioral health resources are a part of this clinic’s program? 
17. What role does social work/care management play in this clinic’s program?  
18. Is there an educational/outreach component (among patients, providers, and/or staff) to the 
program? 
Has not yet implemented 
MAT 
1. What barriers do you anticipate facing in incorporating MAT into practice?  
2. How do you plan to overcome the aforementioned barriers?  
3. What factors do you anticipate will contribute to the clinic’s success?  
4. What model of MAT is the clinic considering?  
5. Have any providers completed the training to prescribe buprenorphine as of yet, or do any plan 
on becoming waivered within the next 6 months? 
6. What do you think is the biggest reason providers choose to/not to become licensed to 
prescribe buprenorphine? 
7. Does the clinic plan on placing restrictions on the types of patients it will accept (e.g. no 
psychiatric comorbidities, only OUD, etc…)? 
8. What feedback have you gotten from providers regarding plans to implement MAT at the 
clinic? 
9. What behavioral health resources will be incorporate into the program? 
10. What role will social work/care management play in the program?  
11. Do you anticipate there being an educational/outreach component (among patients, providers, 
and/or staff)  to the program? 
 
 
Appendix B. AMSTAR Bias Analysis Tool for Systematic Reviews 
 
1. Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist 
maintenance treatments versus agonist maintenance treatments alone for 
treatment of opioid dependence. Cochrane Database Syst Rev. 
2011(10):CD004147. PMID: 21975742. 
Did the research questions and inclusion criteria for the review include the components of PICO? Yes 
Did the report of the review contain an explicit statement that the review methods were established prior to the 
conduct of the review and did the report justify any significant deviations from the protocol? 
Yes 
Did the review authors explain their selection of the study designs for inclusion in the review? Yes 
Did the review authors use a comprehensive literature search strategy? Yes 
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Did the review authors perform study selection in duplicate? Yes 
Did the review authors perform data extraction in duplicate? Yes 
Did the review authors provide a list of excluded studies and justify the exclusions? Yes 
Did the review authors describe the included studies in adequate detail? Yes 
Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were 
included in the review? 
Yes 
Did the review authors report on the sources of funding for the studies included in the review? Yes 
If meta-analysis was performed did the review authors use appropriate methods for statistical combination of results? Yes 
If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the 
results of the meta-analysis or other evidence synthesis? 
Yes 
Did the review authors account for RoB in individual studies when interpreting/ discussing the results of the review? Yes 
Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the 
results of the review? 
Yes 
If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias 
(small study bias) and discuss its likely impact on the results of the review? 
Yes 
Did the review authors report any potential sources of conflict of interest, including any funding they received for 
conducting the review? 
Yes 
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 
2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, 
or both. BMJ. 2017 Sep 21;358:j4008. 
 
2. Gowing, L., Ali, R., White, J.M., Mbewe, D. (2017) Buprenorphine for 
managing opioid withdrawal (Review). Cochrane Database of Systematic 
Reviews, Issue 2. Art No.: CD002025. doi: 10.1002/14651858.CD002025.pub5 
Did the research questions and inclusion criteria for the review include the components of PICO? Yes 
Did the report of the review contain an explicit statement that the review methods were established prior to the 
conduct of the review and did the report justify any significant deviations from the protocol? 
Yes 
Did the review authors explain their selection of the study designs for inclusion in the review? Yes 
Did the review authors use a comprehensive literature search strategy? Partial Yes 
Did the review authors perform study selection in duplicate? Yes 
Did the review authors perform data extraction in duplicate? Yes 
Did the review authors provide a list of excluded studies and justify the exclusions? Yes 
Did the review authors describe the included studies in adequate detail? Yes 
Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies Yes, 
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that were included in the review? included 
only RCTs 
Did the review authors report on the sources of funding for the studies included in the review? Yes 
If meta-analysis was performed did the review authors use appropriate methods for statistical combination of 
results? 
Yes 
If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies 
on the results of the meta-analysis or other evidence synthesis? 
Yes 
Did the review authors account for RoB in individual studies when interpreting/ discussing the results of the 
review? 
Yes 
Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in 
the results of the review? 
Yes 
If they performed quantitative synthesis did the review authors carry out an adequate investigation of 
publication bias (small study bias) and discuss its likely impact on the results of the review? 
Yes 
Did the review authors report any potential sources of conflict of interest, including any funding they received 
for conducting the review? 
Yes 
 
 
Appendix C. Logic Model of Problem of Opioid Use Disorder 
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Appendix D. Logic Model of Proposed Change  
 
Personal 
determinants: 
 
Mental health 
Physical pain/health 
Genetic/physiologic 
reactions 
Prescription access 
Education 
Employment 
Health insurance 
Religiosity 
Negative life events 
Behavioral factors: 
 
Substance use 
Unemployment 
Physical inactivity 
Gang involvement  
Environmental Factors: 
 
Relationship-level: 
Intimate partner 
Parents/family 
Household 
Peers 
Community-level: 
Living arrangement 
Workplace 
School 
Community norms 
Societal-level: 
Discrimination 
Social media 
Socioeconomic status 
Health Problem: 
Opioid Use 
Disorder 
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Change objectives: 
 
Treatment of mental health 
conditions 
Treatment of physical 
health conditions/chronic 
pain 
Consideration of 
genetic/physiologic 
differences 
Prescription 
monitoring/appropriate 
prescribing  
Education 
Gainful employment 
Health insurance coverage 
Encouragement of 
spiritual fulfillment  
Consideration of negative-
life events/trauma-
informed care 
Behavioral change 
outcomes: 
 
Prevention/abstinence from 
substance use 
Gainful employment 
Engagement in physical 
activity 
Avoidance of gang 
involvement  
Environmental change 
outcomes: 
 
Healthier, drug-free 
relationships  
Community-level: 
Safe living 
arrangements 
Drug-free workplace 
Drug-free schools 
Involvement in a 
drug-free community 
(e.g. AA, NA) 
Societal-level: 
No discrimination 
Higher 
socioeconomic status 
Health Problem 
Outcome: 
Remission of OUD 
